Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia

Atherosclerosis

Volumn 247, Issue , 2016, Pages 40-47

  Hernandez Mijares, Antonio ^a,b   Bañuls, Celia ^a,b   Rovira Llopis, Susana ^a,b   Diaz Morales, Noelia ^a   Escribano Lopez, Irene ^a   de Pablo, Carmen ^b   Alvarez, Angeles ^b   Veses, Silvia ^a   Rocha, Milagros ^a,b   Victor, Victor M ^a,b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Atherosclerosis; Ezetimibe; Hypercholesterolemia; Leukocyte endothelium interaction; Mitochondria; Oxidative stress; Simvastatin

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CATALASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EZETIMIBE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYGEN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CELL INTERACTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LEUKOCYTE; MALE; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NEUTROPHIL; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARALLEL DESIGN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; AGED; BLOOD; CELL ADHESION; CELL CULTURE; COCULTURE; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; SPAIN; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CELL ADHESION; CELL ADHESION MOLECULES; CELLS, CULTURED; CHOLESTEROL; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; EZETIMIBE; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LEUKOCYTES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; SIMVASTATIN; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957837877     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.044     Document Type: Article

References (40)

1. Yu E.P., Bennett M.R. Mitochondrial DNA damage and atherosclerosis. Trends Endocrinol. Metab. 2014, 25:481-487.
2. Orio F., Palomba S., Cascella T., Di Biase S., Manguso F., Tauchmanovà L., Nardo L.G., Labella D., Savastano S., Russo T., Zullo F., Colao A., Lombardi G. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90:2-5.
3. Tselepis A.D., John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 2002, 3:57-68.
4. Rocha M., Apostolova N., Herance J.R., Rovira-Llopis S., Hernandez-Mijares A., Victor V.M. Perspectives and potential applications of mitochondria-targeted antioxidants in cardiometabolic diseases and type 2 diabetes. Med. Res. Rev. 2014, 34:160-189.
5. Rodrigues S.F., Almeida-Paula L.D., Granger D.N. Synergistic effects of high blood cholesterol and hypertension on leukocyte and platelet recruitment in the cerebral microcirculation. Hypertension 2014, 63:747-752.
6. Khoretonenko M.V., Brunson J.L., Senchenkov E., Leskov I.L., Marks C.R., Stokes K.Y. Platelets, acting in part via P-selectin, mediate cytomegalovirus-induced microvascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2014, 307:H1745-H1753.
7. Wierzbicki A.S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 2003, 99:95-112.
8. Bonetti P., Lerman L., Napoli C., Lerman A. Statin effects beyond lipid lowering are they clinically relevant?. Eur. Heart J. 2003, 24:225-248.
9. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., Chapman M.J., Dodson P.M., Fioretto P., Ginsberg H.N., Kadowaki T., Lablanche J.M., Marx N., Plutzky J., Reiner Z., Rosenson R.S., Staels B., Stock J.K., Sy R., Wanner C., Zambon A., Zimmet P. Residual Risk Reduction Initiative (R3I). The residual risk reduction initiative: a call of action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc. Dis. Res. 2008, 5:319-335.
10. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 2002, 40:2125-2134.
11. Davidson M.H., Ballantyne C.M., Kerzner B., Melani L., Sager P.T., Lipka L., Strony J., Suresh R., Veltri E. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 2004, 58:746-755. Ezetimibe Study Group.
12. Gryn S.E., Hegele R.A. Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opin. Pharmacother. 2015, 16:1255-1262.
13. Moutzouri E., Liberopulos E.N., Tellis C.C., Milionis H.J., Tselepis A.D., Elisaf M.S. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 2013, 231:8-14.
14. Ray K.K., Kastelein J.J., Boekholdt S.M., Nicholls S.J., Khaw K.T., Ballantyne C.M., Catapano A.L., Reiner Ž., Lüscher T.F. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur. Heart J. 2014, 35:960-968.
15. Hernandez-Mijares, Rocha M., Rovira-Llopis S., Bañuls C., Bellod L., de Pablo C., Alvarez A., Roldan-Torres I., Sola-Izquierdo E., Victor V.M. Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial ischemia. Diabetes Care 2013, 36:1695-1702.
16. Rovira-Llopis S., Bañuls C., Apostolova N., Morillas C., Hernandez-Mijares A., Rocha M., Victor V.M. Is glycemic control modulating endoplasmic reticulum stress in leukocytes of type 2 diabetic patients?. Antioxid. Redox Signal 2014, 21:1759-1765.
17. Berneis K., Rizzo M., Berthold H.K., Spinas G.A., Krone W., Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 2010, 31:1633-1639.
18. Florentin M., Liberopoulos E.N., Moutzouri E., Rizos C.V., Tselepis A.D., Elisaf M.S. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr. Med. Res. Opin. 2011, 27:685-692.
19. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 2002, 40:2125-2134.
20. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., Veltri E.P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415. Ezetimibe Study Group.
21. Morrone D., Weintraub W.S., Toth P.P., Hanson M.E., Lowe R.S., Lin J., Shah A.K., Tershakovec A.M. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261.
22. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., De Ferrari G.M., Ruzyllo W., De Lucca P., Im K., Bohula E.A., Reist C., Wiviott S.D., Tershakovec A.M., Musliner T.A., Braunwald E., Califf R.M., IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372:2387-2397.
23. Ridker P.M., Brown N.J., Vaughan D.E., Harrison D.G., Mehta J.L. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004, 109:6-19.
24. Harrison D., Griendling K.K., Landmesser U., Hornig B., Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 2003, 91:7A-11A.
25. Luft R., Landau B.R. Mitochondrial medicine. J. Intern Med. 1995, 238:405-421.
26. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
27. Anan R., Nakagawa M., Miyata M., Higuchi I., Nakao S., Suehara M., Osame M., Tanaka H. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 1995, 91:955-961.
28. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283:1482-1488.
29. Kostapanos M.S., Milionis H.J., Elisaf M.S. An overview of the extra-lipid effects of rosuvastatin. J. Cardiovasc Pharmacol. Ther. 2008, 13:157-174.
30. McKenney J.M. Pharmacologic characteristics of statins. Clin. Cardiol. 2003, 26. III32-8.
31. Undas A., Machnik A., Potaczek D.P., Wypasek E., Zmudka K., Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J. Cardiovasc Pharmacol. 2011, 58:167-172.
32. Gouni-Berthold I., Berthold H.K., Huh J.Y., Berman R., Spenrath N., Krone W., Mantzoros C.S. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013 Sep 2, 8(9):e72858. 10.1371/journal.pone.0072858.
33. Victor V.M., Rocha M., Bañuls C., Alvarez A., de Pablo C., Sanchez-Serrano M., Gomez M., Hernandez-Mijares A. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J. Clin. Endocrinol. Metab. 2011, 96:3115-3122.
34. Krieglstein C.F., Granger D.N. Adhesion molecules and their role in vascular disease. Am. J. Hypertens. 2001, 14:44S-54S.
35. Rao R.M., Yang L., Garcia-Cardena G., Luscinskas F.W. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ. Res. 2007, 101:234-247.
36. Kar S., Kavdia M. Local oxidative and nitrosative stress increases in the microcirculation during leukocytes-endothelial cell interactions. PLoS One 2012, 7:e38912.
37. Victor V.M., Rocha M., Bañuls C., Alvarez A., de Pablo C., Sanchez-Serrano M., Gomez M., Hernandez-Mijares A. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J. Clin. Endocrinol. Metab. 2011, 96:3115-3122.
38. Miyahara S., Kiryu J., Yamashiro K., Miyamoto K., Hirose F., Tamura H., Katsuta H., Nishijima K., Tsujikawa A., Honda Y. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am. J. Pathol. 2004, 164:1697-1706.
39. Rezaie-Majd A., Prager G.W., Bucek R.A., Schernthaner G.H., Maca T., Kress H.G., Valent P., Binder B.R., Minar E., Baghestanian M. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2003, 23:397-403.
40. Cerda A., Rodrigues A.C., Alves C., Genvigir F.D., Fajardo C.M., Dorea E.L., Gusukuma M.C., Pinto G.A., Hirata M.H., Hirata R.D. Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients. Cardiovasc Ther. 2015, 33:168-176.